Semax: Research, Mechanism of Action & Scientific Overview

What Is Semax?

Semax is a synthetic heptapeptide (seven amino acids) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It was designed as a modified fragment of the naturally occurring ACTH(4-10) sequence, with a Pro-Gly-Pro tail added to the C-terminus to dramatically increase its resistance to enzymatic degradation. In Russia, Semax has been used clinically since the late 1990s for ischemic stroke, cognitive disorders, and optic nerve neuropathy.

Although derived from ACTH, Semax has been stripped of the hormonal activity of its parent molecule, it does not stimulate cortisol or glucocorticoid release. What remains is the neurotropic component of ACTH, which acts primarily on the central nervous system. This makes Semax one of the most widely studied "nootropic" peptides in the published literature.

Key Identifier

Peptide Profile

Full Name: Semax
Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)
Molecular Weight: ~813.9 Da
Amino Acid Residues: 7 (heptapeptide)
Classification: ACTH(4-10) analog, nootropic peptide, neuropeptide
Developer: Institute of Molecular Genetics (Russia)

Mechanism of Action

Semax acts primarily within the central nervous system through multiple, interconnected mechanisms. Research has identified effects on neurotrophic factor expression, monoaminergic signaling, and cellular resistance to oxidative stress.

BDNF and Neurotrophic Factor Modulation

One of the most well-characterized effects of Semax is its ability to upregulate the expression of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, as well as nerve growth factor (NGF), in key brain regions including the hippocampus and basal forebrain. BDNF is central to neuronal survival, synaptic plasticity, and long-term memory consolidation, making this a plausible mechanistic basis for the cognitive effects observed in research.

Monoaminergic System Effects

Preclinical studies have shown Semax influences the dopaminergic and serotonergic systems. Research has demonstrated modulation of dopamine and serotonin turnover in the striatum and limbic regions, which may underlie its reported effects on attention, motivation, and mood in animal models. Unlike classical stimulants, Semax does not appear to cause acute dopamine flooding or reinforce addictive behaviors in preclinical research.

Neuroprotection and Antioxidant Activity

Semax has been studied in ischemic and oxidative stress models where it demonstrated neuroprotective properties. Proposed mechanisms include modulation of pro- and anti-apoptotic gene expression, reduction of inflammatory cytokine release, and enhancement of endogenous antioxidant defenses. These effects underpin its clinical use in stroke research in Russia.

Enhanced Peptidase Resistance

The native ACTH(4-10) fragment is degraded within minutes in the body. The addition of the Pro-Gly-Pro (PGP) tripeptide to the C-terminus of Semax dramatically increases its resistance to enzymatic cleavage, extending its functional half-life and allowing for intranasal administration, the most commonly studied route in both preclinical and clinical research.

Research Overview

Semax has been investigated in an extensive body of Russian and international literature covering cognitive, neuroprotective, and psychoemotional research endpoints. The following table summarizes key areas of investigation.

Research Area	Key Findings	Study Type
Cognitive Performance	Studies demonstrate improvements in attention, working memory, and task performance in both healthy and cognitively impaired models	In vivo (human/rodent)
BDNF Expression	Research demonstrates upregulation of BDNF and TrkB receptor expression in hippocampus and basal forebrain	In vivo (rodent)
Ischemic Stroke	Clinical studies in Russia have evaluated Semax as adjunct therapy in acute ischemic stroke with reduced neurological deficit	In vivo (human)
Neuroprotection	Preclinical models of cerebral ischemia and oxidative stress show reduced neuronal loss and improved functional recovery	In vivo (rodent)
Attention / ADHD	Pilot clinical research has examined Semax in attention disorders and cognitive fatigue	In vivo (human)
Anxiolytic / Psychoemotional	Animal studies indicate stress-resistance and anxiolytic-like effects without sedation	In vivo (rodent)

Research Context

Semax has one of the more extensive clinical research histories among peptides in its class, particularly within Russian neurology. Published studies have evaluated Semax in healthy subjects, ischemic stroke patients, and individuals with cognitive impairment, alongside a large body of preclinical rodent work on BDNF, neurotrophic gene expression, and behavioral endpoints.

Common Areas of Research Interest

Scientific interest in Semax centers on its unusual combination of cognitive, neuroprotective, and psychoemotional effects, along with its demonstrated safety profile in Russian clinical use.

Cognitive performance, Semax is studied for effects on attention, working memory, learning, and task completion in both healthy and impaired models
Neuroprotection, Research has investigated Semax in ischemic, hypoxic, and oxidative stress models of neuronal injury
Stroke recovery, Clinical research in Russia has examined Semax as adjunct therapy in acute ischemic stroke
BDNF modulation, Studies have identified Semax as a potent inducer of BDNF and NGF expression in the CNS
Attention disorders, Pilot research has explored Semax in pediatric attention disorders and adult cognitive fatigue
Psychoemotional balance, Preclinical studies indicate stress-buffering and anxiolytic-like effects without sedation or dependence liability

Pharmacokinetics

The pharmacokinetic profile of Semax is characterized by its PGP-stabilized structure, which extends biological activity far beyond the native ACTH(4-10) fragment. The following parameters summarize key pharmacokinetic characteristics reported in the literature.

~24 hrs

Functional Duration (CNS)

813.9

Molecular Weight (Da)

Amino Acid Residues

IN / SC

Administration Route

While Semax has a relatively short plasma half-life (on the order of 20–30 minutes), the PGP C-terminal modification dramatically extends its functional effects within the CNS, with research showing gene expression changes and neurotrophic effects persisting for up to 24 hours after a single dose. Semax is most commonly studied via intranasal administration, which bypasses first-pass metabolism and provides efficient nose-to-brain delivery; subcutaneous administration has also been reported in research.

Comparison to Similar Peptides

Semax sits within a broader class of CNS-active nootropic and neuropeptide compounds. The following comparison highlights key distinctions among these peptides.

Feature	Semax	Selank	Noopept	Cerebrolysin	Dihexa
Classification	ACTH(4-10) analog	Tuftsin analog	Synthetic dipeptide	Neuropeptide mixture	Angiotensin IV analog
Amino Acids	7	7	Non-peptide	Mixture	6
Plasma Half-Life	~20–30 min	~15–30 min	~30 min	Variable	~10 days (oral)
Primary Target	BDNF/NGF, monoamines	GABAergic, stress axis	BDNF, NGF, AMPA	Trophic/neurotrophic	HGF/c-Met pathway
Primary Use Case	Cognitive / neuroprotection	Anxiolytic / cognitive	Memory / cognition	Stroke / dementia	Memory enhancement
Typical Route	Intranasal	Intranasal	Oral	IM / IV	Oral

Frequently Asked Questions

What is Semax and where does it come from?

Semax is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. It is a modified fragment of the natural ACTH(4-10) sequence, with a Pro-Gly-Pro tail added to increase its stability. Semax has been used clinically in Russia since 1996 for conditions including ischemic stroke, optic neuropathy, and cognitive disorders.

Does Semax stimulate cortisol since it's derived from ACTH?

No. Although Semax is derived from a fragment of ACTH, the sequence was specifically chosen and modified to eliminate the steroidogenic (cortisol-releasing) activity of the parent hormone while preserving its neurotropic effects. Research has consistently shown that Semax does not elevate cortisol, corticosterone, or HPA-axis markers. This is a key reason it is considered a clean nootropic compound.

How is Semax typically administered in research?

In the published research, the most common route of administration is intranasal, leveraging direct nose-to-brain delivery through the olfactory and trigeminal pathways. This route avoids first-pass metabolism and delivers the peptide efficiently to CNS targets. Subcutaneous administration has also been used in some research protocols. Semax is typically reconstituted in bacteriostatic water and administered in small metered doses in research settings.

What does the research say about Semax and BDNF?

One of the most consistent findings in Semax research is upregulation of brain-derived neurotrophic factor (BDNF) expression and its TrkB receptor, particularly in the hippocampus and basal forebrain. BDNF is central to synaptic plasticity, long-term memory, and neuronal survival, making this mechanism a plausible basis for the cognitive and neuroprotective effects observed in both preclinical and clinical research.

Has Semax been used clinically?

Yes, in Russia. Semax is an officially registered pharmaceutical there and has been used clinically since 1996. Russian clinical applications have included ischemic stroke (as part of standard acute stroke protocols), transient ischemic attacks, optic nerve atrophy, and pediatric attention disorders. However, Semax is not FDA-approved and is not used clinically in the United States, where it remains a research compound.

What does the research show about Semax?

Published research on Semax spans rodent cognitive/behavioral studies, gene expression studies on BDNF and NGF, and human clinical studies in ischemic stroke and cognitive disorders. Findings consistently show neurotrophic factor upregulation, neuroprotective effects in ischemic models, and improvements in attention and cognitive performance endpoints. Research output comes primarily from Russian institutions, with peer-reviewed findings available through PubMed and international journals.

Sources & References

Kaplan AYa, et al. "Synthetic ACTH analog Semax displays nootropic-like activity in humans." Neuroscience Research Communications. 1996;19(2):115-123.
Shadrina MI, et al. "Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog." Neuroscience Letters. 2001;308(2):115-118. PubMed
Dolotov OV, et al. "Semax, an analog of ACTH(4-10), binds specifically and increases levels of brain-derived neurotrophic factor in the basal forebrain of rats." Journal of Neurochemistry. 2006;97(Suppl 1):82-86. PubMed
Gusev EI, Skvortsova VI, Miasoedov NF, et al. "Effectiveness of semax in acute period of hemispheric ischemic stroke." Zhurnal Nevrologii i Psikhiatrii. 2005;105(6):24-28. PubMed
Medvedeva EV, et al. "The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia." Doklady Biochemistry and Biophysics. 2013;450:110-114. PubMed
Levitskaya NG, Kamensky AA. "Protective effects of Semax in models of oxidative stress." Neurochemical Research. 2010.
Myasoedov NF, et al. "Semax in prevention of disease relapses and early disability in patients with circulatory encephalopathy." Zhurnal Nevrologii i Psikhiatrii. 2010;110(5):31-37. PubMed
Eremin KO, et al. "Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents." Neurochemical Research. 2005;30(12):1493-1500. PubMed

Explore Semax 10mg

Available for research purposes. Third-party tested for purity and identity.

View Semax — $65

This product is intended for research and laboratory use only. It is not intended for human consumption.

Disclaimer: This content is provided for educational and informational purposes only. It is not intended as medical advice, nor does it constitute a recommendation for the treatment, cure, or prevention of any disease or condition. Semax is sold for research purposes only and is not intended for human consumption. Always consult a qualified healthcare professional before making decisions about your health. Somata Peptides does not claim that any products treat, cure, or prevent any disease.